US EditionUS FDA clears phase 3 clinical study of ASI-02 in patients undergoing TTE
Summary by Cardiovascular News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
US FDA clears phase 3 clinical study of ASI-02 in patients undergoing TTE
The US Food and Drug Administration (FDA) has cleared Agitated Solutions Incorporated’s (ASI’s) investigational new drug (IND) application for its novel contrast agent, ASI-02, enabling the initiation of the company’s phase 3 clinical trial. This multicentre randomised study will assess the safety and efficacy of ASI-02 in up to 300 patients in the USA and Canada undergoing transthoracic echocardiography (TTE) with agitated saline contrast—commo…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
